Validation of Innovative Lipopeptide Antibiotics

Project Information

VOILA

Grant agreement ID: 838321

DOI

10.3030/838321

Project closed

EC signature date 15 March 2019

Start date 1 April 2019

End date 31 March 2021

Funded under

• EXCELLENT SCIENCE - European Research Council (ERC)

Total cost

€ 150 000,00

EU contribution

€ 150 000,00

Coordinated by

UNIVERSITEIT LEIDEN
Netherlands

Periodic Reporting for period 1 - VOILA (Validation of Innovative Lipopeptide Antibiotics)

Reporting period: 2019-04-01 to 2021-03-31

Summary of the context and overall objectives of the project

The ERC proof of concept (PoC) project titled "Validation Of Innovative Lipopeptide Antibiotics" (acronym VOILA) involved the further development of a novel class of semisynthetic lipopeptide antibiotics recently discovered by researchers at Leiden University. These new lipopeptide antibiotics demonstrate dramatically enhanced activities compared with clinically used antibiotics like vancomycin, one of the most frequently prescribed glycopeptide antibiotics. Notably, these new antibiotics are highly active against drug resistant bacteria including methicillin-resistant S. aureus (MRSA) and vancomycin-resistant enterococci (VRE). Importantly, the studies conducted as part of this ERC-PoC project demonstrated that the new lipopeptide antibiotics are highly effective in advanced in vivo infection models. These findings support the further pre-clincial development of these promising new antibiotic agents.